ASX News

Telix Progresses Novel Lung and Ovarian Cancer Theranostic APOMAB®

Melbourne and Adelaide (Australia) – 17 August 2021. Telix extends partnership with AusHealth relating to APOMAB®, a novel theranostic being investigated in lung and ovarian cancers

Telix today announces it has extended its partnership with AusHealth Corporate Pty Ltd relating to APOMAB®, a novel therapeutic and diagnostic technology platform being investigated in lung and ovarian cancers.

Specifically, Telix has exercised an option granted in 2019 to in-licence the antibody, based on encouraging preliminary clinical data from a Phase I imaging study that forms part of the current academic collaboration.

APOMAB is an antibody targeting the La/SSB protein, which is specifically expressed by cancer cells that have been treated with chemotherapy and/or radiation. This investigational asset is the subject of an ongoing clinical study being conducted by the Central Adelaide Local Health Network (CALHN), led by Royal Adelaide Hospital (RAH) Cancer Clinical Trials Unit Head, Professor Michael Brown. This Phase I proof-of-concept study is initially using zirconium-89 labelled antibody (89Zr-APOMAB) to evaluate the biological properties and safety of the agent using positron emission tomography (PET) imaging.

With early results demonstrating the potential suitability of APOMAB to safely deliver targeted radiation to advanced lung and ovarian cancers, a follow-on study is currently in planning to accelerate the development of a next generation version of APOMAB labelled with a therapeutic isotope such as lutetium-177 (177Lu).

The trial’s Principal Investigator Professor Michael Brown said, “After years of research at RAH exploring the unique mechanism and potential of APOMAB to diagnose and treat cancer in preclinical models, it is highly pleasing to see this technology demonstrate targeted delivery of radiation to tumours in clinical settings.”

Telix CEO Dr Christian Behrenbruch stated, “Having established a clinical proof-of-concept, we are motivated to progress the licence for this promising technology platform, which has potential as a targeting agent for both imaging and therapy in multiple cancer indications. The next stage in this academic-industry partnership is to take APOMAB into therapeutic studies, with the ultimate aim of commercialisation. We would like to thank Professor Brown and his clinical team at RAH, and most importantly the patients who have contributed to this ground-breaking study.”

AusHealth Managing Director and CEO Greg Johansen added, “Our early research demonstrated that APOMAB binds cancer cells after cytotoxic anticancer treatment. It’s brilliant to see the same binding effect taking place in APOMAB-dosed cancer patients. The APOMAB clinical trial conducted at the Royal Adelaide Hospital shows what can take place when an innovative medical concept is developed into a ‘results driven’ partnership led by AusHealth and by vital industry partners such as Telix. This clinical proof-of-concept strengthens our confidence that APOMAB will become a vital tool, useful in both theranostic and therapeutic applications in clinical settings.”

To read the full media release please click here.

To return to Telix’s homepage please click here.

More Articles

Corporate Spotlight

Second Industry Body Updates Guidance for Use of PSMA PET Imaging

Melbourne (Australia) and Indianapolis, IN (U.S.A.) – 21 September 2021. Telix welcomes SNMMI updated Appropriate Use Criteria for PSMA PET...

Corporate Spotlight

Telix at AdMeTech Summit on Precision Diagnosis and Treatment of Prostate Cancer

16 September 2021 – Clinical Spotlight | Telix to support and participate in AdMeTech 5th Global Summit on Precision Diagnosis...

ASX News

NCCN Guidelines Updated to Include PSMA-PET Imaging

Melbourne (Australia) and Indianapolis, IN (U.S.A.) – 14 September 2021. Telix welcomes the updated NCCN Guidelines® for prostate cancer, which includes...

ASX News

FDA Approves Phase II Kidney Cancer Therapy Study

Melbourne (Australia) and Indianapolis, IN (U.S.A.) – 14 September 2021. Telix announces the FDA has accepted the IND Application to...

ASX News

Telix and Radius Sign Italian Distribution Agreement for Prostate Cancer Imaging

Melbourne (Australia) and Bologna (Italy) – 13 September 2021. Telix enters a commercial distribution agreement with Radius for Telix’s prostate...

ASX News

Japanese Prostate Cancer Imaging Study Completes Enrolment

Melbourne (Australia) and Kyoto (Japan) – 9 September 2021. Telix has completed a Phase I clinical trial of TLX591-CDx for...

ASX News

Telix to Collaborate with Kettering Health on Diagnostic PSMA Imaging & Targeting Theranostics

Melbourne (Australia), Indianapolis (IN, U.S.A.), and Kettering (OH, U.S.A.) – 7 September 2021. Telix announces collaboration with Kettering Health on...

ASX News

Telix and Lightpoint Medical to Collaborate on Radioguided Surgery

Melbourne (Australia) – 23 August 2021. Telix announces collaboration with Lightpoint Medical to explore molecularly targeted radiation and Lightpoint SENSEI®...

ASX News

Telix Half-Year Results 2021 and Company Update Conference Call

Melbourne (Australia) – 19 August 2021. Telix announces Half-Year Results 2021 and provides shareholder update

ASX News

Telix Expands Prostate Cancer Activity with GenesisCare Collaboration

Melbourne (Australia) – 19 August 2021. Telix releases details of two ancillary studies under the ProstACT program, including a Phase...

ASX News

Telix and Merck to Commence Pan-Cancer Clinical Combination Studies

Melbourne (Australia) – 18 August 2021. Telix announces pan-cancer clinical collaboration with Merck KGaA, Darmstadt, Germany.

ASX News

Two New Studies to Explore Telix Assets in Breast Cancer Theranostics

Melbourne (Australia) – 18 August 2021. Telix announces two new studies to evaluate the potential utility of TLX591-CDx and TLX250-CDx...

ASX News

Telix Progresses Novel Lung and Ovarian Cancer Theranostic APOMAB®

Melbourne and Adelaide (Australia) – 17 August 2021. Telix extends partnership with AusHealth relating to APOMAB®, a novel theranostic being...

ASX News

Telix’s TLX66 in Phase II Academic Study of Pediatric Leukemia

Melbourne (Australia) and London (United Kingdom) – 17 August 2021. Telix announces Phase II academic study of TLX66 in children...

ASX News

Telix H1 2021 Results and Company Update Conference Call

Melbourne (Australia) – 11 August 2021. Telix to hold investor conference call to present H1 2021 financial results and Company...

ASX News

First Patient Dosed in CUPID Study of Telix’s Targeted Alpha Therapy Candidate for Prostate Cancer

Melbourne (Australia) – 5 August 2021. Telix announces the first patient has been dosed in its ‘CUPID’ Phase I study...

Corporate Spotlight

Ms. Helen Hovenga Joins Telix as Chief People Officer

4 August 2021 – Corporate Spotlight | Telix announces the appointment of Ms. Helen Hovenga in the role of Chief...

ASX News

Telix Seneffe Production Facility: Progress Update

Melbourne (Australia) and Seneffe (Belgium) – 30 July 2021. Telix authorised to decommission first of two cyclotrons at Seneffe radiopharmaceutical...

ASX News

Activities Report and Appendix 4C for June 2021 Quarter

Melbourne (Australia) – 22 July 2021. Telix provides its Appendix 4C and accompanying Activities Report for the quarter ended 30 June...

ASX News

ZIRCON Phase 3 Renal Cancer Imaging Study: Progress Update

Melbourne (Australia) – 20 July 2021. Progress update on the ZIRCON Phase 3 study for the imaging of renal cancer...

Corporate Spotlight

Telix Appoints Gabrielle Wermenbol as Chief Financial Officer, EMEA

19 July 2021 – Corporate Spotlight | Gabrielle Wermenbol joins Telix as Chief Financial Officer, Europe, Middle East & Africa...

Corporate Spotlight

Kyahn Williamson Joins Telix to Lead Corporate Communications and Investor Relations

Melbourne (Australia) – 12 July 2021. Telix announces that Ms. Kyahn Williamson has joined the Telix executive leadership team in...

ASX News

First Patient Dosed in Clinical Study of TLX250-CDx in Bladder Cancer

Melbourne (Australia) – 23 June 2021. Telix announces that a first patient has been dosed in a Phase I study...

ASX News

IPAX-1 (TLX101 for Glioblastoma Therapy) Clinical Trial Update

Melbourne (Australia) – 21 June 2021. Telix announces preliminary safety data from the IPAX-1 Ph I/II study, with a follow-on...

ASX News

Telix Update on FDA New Drug Application Review for Illuccix®

Melbourne (Australia) and Indianapolis, IN (U.S.A.) – 17 June 2021. Telix announces participation in a late-cycle meeting with the U.S....

Corporate Spotlight

Telix Pharmaceuticals and Applied Radiology launch TelixU Medical Education Platform Focused on Radiopharmaceutical Research

MELBOURNE, Australia and INDIANAPOLIS 14 June, 2021 – Telix announces the launch of a new educational platform focused on radiopharmaceutical...

Corporate Spotlight

Telix launches “Gallium Wave” Awareness Website

Melbourne (Australia) and Indianapolis (U.S.A.) – 11 June 2021. Telix announces the launch of a new website “Gallium Wave”, as...

Corporate Spotlight

Scott Law joins Telix as SVP Global Manufacturing Operations

11 June 2021 – Corporate Spotlight | Scott Law joins Telix as Senior Vice President Global Manufacturing Operations

ASX News

Telix and ATS Awarded $1.56M ‘Eurostars’ Grant for Alpha Therapy

Liège (Belgium) and Gothenburg (Sweden) – 7 June 2021. Advanced Nuclear Medicine Ingredients S.A, a wholly owned European subsidiary of...